ABL Diagnostics Appointed by NLPH for Next Generation Sequencing Solutions
On Monday 13 May, 2024, ABL Diagnostics, a company listed on Euronext, announced its partnership with its exclusive distributor, Laborama Co. Ltd., for the provision of Next Generation Sequencing (“NGS”) solutions to the National Laboratory for Public Health (NLPH) in Lithuania.
Under a two-year agreement, ABL Diagnostics and Laborama will work together to implement NGS solutions for various microbiology applications at NLPH, including HIV, SARS-CoV-2, Influenza A, Influenza B, and other pathogens. This partnership will provide NLPH with robust and innovative assays, library preparation reagents, and software solutions.
According to a market assessment report by DeciBio, the NGS market was valued at approximately $6.5 billion in 2023 and is expected to grow at a rate of 13% annually, reaching $9.4 billion in 2026. With the increasing adoption of NGS technology in clinical settings, especially amidst the COVID-19 pandemic, it is now the largest segment of the market. ABL Diagnostics’ reagents are critical in this field.
Marius Savickas, managing director at Laborama, Interlux Group company, expressed his excitement about expanding their partnership with ABL Diagnostics to include other relevant applications. “We are extremely pleased to keep supporting NLPH for implementing innovative NGS technologies,” he said.
Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics, added, “ABL Diagnostics is honored to help NLPH and to supply our latest NGS-based technologies, which shall help optimize the management of key diseases in the country for the next decades.”
The detailed terms of the agreement have not been disclosed.
ABL Diagnostics is a worldwide leading international company that offers innovative and proprietary molecular biology assays and end-to-end solutions for molecular detection and genotyping. Their products cover a wide range of microbiology applications, including HIV, SARS-CoV-2, Tuberculosis, and viral hepatitis B and C.
The company has a global reach and works with over 50 exclusive distributors. They also develop, manufacture, and market kits for clinical specimen collection and digital solutions like Nadis®, an Electronic Medical Record (EMR) system used in over 200 hospitals in France.
Laborama, a part of Interlux Group, has been providing innovative and top-quality technologies and solutions to the customers of the Baltic region for 30 years. They specialize in scientific and clinical research technologies and provide supplies for researchers and users of advanced laboratory technologies.
Marius Savickas, Managing Director of Laborama, emphasized their commitment to providing effective and high-quality solutions to their customers. “We aim to offer each customer a solution that best meets the needs of a specific laboratory or research center,” he said.
For further information, please visit www.abldiagnostics.com and www.laborama.lt.
This press release contains implicitly or explicitly certain forward-looking statements concerning ABL Diagnostics and its business. These statements are based on assumptions that ABL Diagnostics considers to be reasonable but are subject to numerous risks, including those set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022. The occurrence of these risks could cause actual results, financial conditions, performance, or achievements of ABL Diagnostics to be materially different from the forward-looking statements.
This press release and the information contained herein do not constitute an offer or invitation to sell or subscribe for ABL Diagnostics shares in any country. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
Distributed by https://pressat.co.uk/
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.